About Bionano
Bionano is a company based in San Diego (United States) founded in 2002. Bionano has raised $124.2 million across 27 funding rounds from investors including NIH, HHS and National Cancer Institute. The company has 100 employees as of December 31, 2024. Bionano has completed 1 acquisition, including BioDiscovery. Bionano operates in a competitive market with competitors including Nanopore, PacBio, Omniome, Complete Genomics and QuantuMDx, among others.
- Headquarter San Diego, United States
- Employees 100 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Bionano Genomics, Inc.
-
Annual Revenue
$30.78 M (USD)-14.79as on Dec 31, 2024
-
Net Profit
-$112.02 M (USD)51.82as on Dec 31, 2024
-
EBITDA
-$71.48 M (USD)43.14as on Dec 31, 2024
-
Total Equity Funding
$124.2 M (USD)
in 27 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
May 24, 2024
-
Investors
NIH
& 15 more
-
Employee Count
100
as on Dec 31, 2024
- Investments & Acquisitions
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Bionano
Bionano is a publicly listed company on the NASDAQ with ticker symbol BNGO in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Bionano
Unlock access to complete
Funding Insights of Bionano
Bionano has successfully raised a total of $124.2M across 27 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Bionano
Bionano has secured backing from 16 investors, including venture fund and institutional investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture Capital firm focused on multiple sectors
|
Locked | Locked | Locked | |
|
Investments are made in innovative life science companies globally.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Bionano
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bionano
Bionano has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include BioDiscovery.
Investment portfolio details for Bionano
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Software solutions for microarray and next-generation sequencing analysis are provided.
|
Locked | Locked | 1997 | Locked |
Complete acquisition details for Bionano
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Bionano
Detailed financials for Bionano
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Bionano Comparisons
Peer comparison for Bionano
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Bionano
Bionano operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nanopore, PacBio, Omniome, Complete Genomics and QuantuMDx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Nanopore-based electronic systems for single-molecule analysis are developed.
|
|
| Locked | Locked | Locked |
Instrument systems and software for single-molecule real-time sequencing are developed.
|
|
| Locked | Locked | Locked |
Genome sequencing platform is provided for clinical diagnostics.
|
|
| Locked | Locked | Locked |
DNA sequencing platform for human genome analysis is developed.
|
|
| Locked | Locked | Locked |
Handheld diagnostic and sequencing devices are developed for personalized healthcare.
|
Detailed competitors of Bionano
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Bionano
Complete news archive for Bionano
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bionano
Bionano was founded in 2002 and raised its 1st funding round 3 years after it was founded.
Bionano is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Erik Holmlin is the current CEO of Bionano.
Bionano is a funded company, having raised a total of $124.2M across 27 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Bionano is 100.
Annual revenue of Bionano is $30.78M as on Dec 31, 2024.
Founded in 2002 and based in San Diego, United States, Bionano operates in the biotechnology sector, focusing on genome analysis tools. The Saphyr system is utilized for non-sequencing optical mapping of long genomic DNA strands. This technology is applied to identify structural variants overlooked by next-generation sequencing and traditional cytogenetic methods, supporting research and clinical applications.
Yes, Bionano is publicly traded on NASDAQ under the ticker symbol BNGO.
Bionano has made 1 acquisition, including BioDiscovery.
Bionano has 16 investors. Key investors include NIH, HHS, National Cancer Institute, Ben Franklin Technology Partners, and NHGRI.
The ticker symbol of Bionano is BNGO on NASDAQ.